Dr. Estey is an expert in the treatment of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). In addition to seeing patients at the UWMC and at SCCA, he has considerable experience in the design, conduction, and interpretation of clinical trials in AM. He is particularly interested in bringing data to bear on the clinical management of AML.
Dr. Estey received his degree in mathematics at Yale University, New Haven, CT before attending medical school at Johns Hopkins University, Baltimore, MD. He did residency training in New York’s Bellevue Hospital in neurology. His neurology training led him to an interest in brain tumors and he went on to MD Anderson Cancer Center in Houston to work with oncology pioneer, Dr. Emil Freireich, who in the 1960s was the first to use combination chemotherapy to cure childhood acute lymphocytic leukemia (ALL).
Dr. Estey worked at MD Anderson for nearly 30 years. He and his family decided to relocate to the Seattle area in 2007 for a change of scenery, and so he could help build an AML program at Seattle Cancer Care Alliance. Dr. Estey is board certified in internal medicine, hematology, and medical oncology. He is a member of the American Society of Hematology, American Society of Clinical Oncology, and the American Society of Cancer Research.